The FDA recently approved the first cellular immunotherapies to treat certain blood cancers. But so far, these T cell immunotherapies can't be used if the T cells themselves are cancerous. Such 'CAR-T' cells kill each other because they resemble one another so closely. Scientists now have used the gene-editing technology CRISPR to engineer human T cells that can attack human T cell cancers without succumbing to friendly fire.
from Top Health News -- ScienceDaily http://ift.tt/2oUnyZL
No comments:
Post a Comment